STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13G: Squadron Reports 5.3%–6.0% Ownership in TRAW

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Schedule 13G filed for Traws Pharma, Inc. (TRAW) reports that Squadron Master Fund LP holds 372,374 shares (5.3%) and that Squadron Capital Management LLC and principals Matthew Sesterhenn and William Blank each report 420,501 shares (6.0%) based on 7,063,829 shares outstanding as of August 12, 2025. The filing states the shares are held by funds advised by Squadron Capital and that the adviser and the named partners disclaim beneficial ownership under Rule 13d-4. No party reports sole voting or dispositive power; all reported holdings are shared.

Positive

  • Institutional stake disclosed: Squadron Master Fund LP reports a 5.3% stake and related parties report 6.0%, crossing the 5% SEC reporting threshold
  • Transparency: The filing provides clear share counts and percentages based on the issuer's stated outstanding shares

Negative

  • No sole voting or dispositive power: All reported shares are listed as shared, indicating limited direct control by the filers
  • Disclaimer of beneficial ownership: Squadron Capital Management LLC and the named partners expressly disclaim beneficial ownership under Rule 13d-4, which may limit the perceived intent to influence control

Insights

TL;DR: A fund and its adviser disclosed stakes above 5%, potentially attracting investor attention but without asserted control.

The filing shows institutional accumulation: Squadron Master Fund LP owns 5.3% and related adviser and partners each report 6.0% of Traws Pharma, based on the issuer's outstanding share count. Stakes above 5% are material and may prompt market scrutiny or activist interest, yet the disclaimer under Rule 13d-4 and the absence of sole voting/dispositive power indicate the filers are not asserting control. For valuation or trading impact, market reaction will depend on additional context such as prior ownership disclosures and any subsequent filings.

TL;DR: Reported holdings exceed the 5% reporting threshold but the filers disclaim beneficial ownership and report only shared powers.

From a governance perspective, the disclosure is significant because ownership above 5% requires transparency on intentions and potential influence. However, the explicit Rule 13d-4 disclaimer and the lack of sole voting or dispositive power suggest the filers are signaling no attempt to change control. This maintains the status quo for board and management oversight unless follow-on filings reveal coordination or changes in voting arrangements.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:09/19/2025
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:09/19/2025
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:09/19/2025
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:09/19/2025

FAQ

What stake did Squadron Master Fund LP report in TRAW?

The filing reports 372,374 shares (5.3%) beneficially owned by Squadron Master Fund LP.

How many shares and what percentage did Squadron Capital Management LLC report?

Squadron Capital Management LLC reported 420,501 shares (6.0%) based on 7,063,829 shares outstanding.

Do the filers claim control of Traws Pharma (TRAW)?

No. The filers state they have no sole voting or dispositive power and expressly disclaim beneficial ownership under Rule 13d-4.

On what outstanding share count are the percentages based?

Percentages are based on 7,063,829 shares outstanding as represented by the issuer for August 12, 2025.

Who signed the Schedule 13G for the reporting parties?

The filing is signed by Matthew Sesterhenn for Squadron Master Fund LP and Squadron Capital Management LLC, and by William Blank individually.
Traws Pharma

NASDAQ:TRAW

TRAW Rankings

TRAW Latest News

TRAW Latest SEC Filings

TRAW Stock Data

18.86M
6.34M
14.86%
17.89%
1.45%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWTOWN